Approval · Notice of Compliance 4836 · 2004
CO GABAPENTIN: Notice of Compliance 4836
Issued August 13, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4836
- Date
- August 13, 2004
- Company
- Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Anti-epileptic agent
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CO GABAPENTIN | 02256142 | Cancelled Post Market |
| CO GABAPENTIN | 02256150 | Cancelled Post Market |
| CO GABAPENTIN | 02256169 | Cancelled Post Market |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP